Öz
Entekavir, Hepatit B enfeksiyonunun tedavisinde kullanılan önemli bir nükleozid analoğudur. Bu olgu sunumunda, entekavir tedavisi alırken bilateral jinekomasti ve mastodoni gelişen bir olgu sunulması amaçlanmıştır.
Anahtar Kelimeler
Kaynakça
- 1. Karagoz E, Selek MB, Tanoglu A, Hatipoglu M, Ulçay A, Turhan V. Comparison of the elecsys HBsAg II assay and the architect assay for quantification of hepatitis B surface antigen in patients with chronic hepatitis B. Infez Med. 2016;24(4):287-292.
- 2. Karagöz E, Tanoğlu A. Importance of serum hepatitis B surface antigen and hepatitis e antigen quantification among patients with chronic hepatitis B. Turk J Gastroenterol. 2015;26:357.
- 3. Nikolopoulou GB, Tzoutzas I, Tsakris A, Maltezou HC. Hepatitis B in healthcare personnel: an update on the global landscape. Viruses. 2023;15(12):2454. doi: 10.3390/v15122454
- 4. Karagoz E, Ulcay A, Tanoglu A, et al. Clinical usefulness of mean platelet volume and red blood cell distribution width to platelet ratio for predicting the severity of hepatic fibrosis in chronic hepatitis B virus patients. Eur J Gastroenterol Hepatol. 2014;26(12):1320-1324.
- 5. Koklu S, Gulsen MT, Tuna Y, et al. Differences in nephrotoxicity risk and renal effects among anti-viral therapies against hepatitis B. Aliment Pharmacol Ther. 2015;41(3):310-319.
- 6. Deepinder F, Braunstein GD. Drug-induced gynecomastia: an evidence-based review. Expert Opin Drug Saf. 2012;11(5):779-795. doi: 10.1517/14740338.2012.712109
- 7. Berger O, Landau Z, Talisman R. Gynecomastia: a systematic review of pharmacological treatments. Front Pediatr. 2022;10:978311. doi: 10.3389/fped.2022.978311
- 8. Henriquez-Camacho C, Hijas-Gomez AI, Risco Risco C, Ruiz Lapuente MA, Escudero-Sanchez R, Cuerda VM. Lamivudine and entecavir for acute hepatitis B: a systematic review and meta-analysis. Viruses. 2023;15(11):2241. doi: 10.3390/v15112241
- 9. Bayramıçlı OU, Ahishali E, Dabak R, Ak Ö, Dolapçioğlu C. A case of gynecomastia due to entecavir. Turk J Gastroenterol. 2010;21(3):313-316. doi: 10.4318/tjg.2010.0108
Öz
Entecavir is an important nucleoside analogue that plays a pivotal role in the treatment of Hepatitis B infection. In this case report, it was aimed to present a case regarding bilateral gynecomastia and mastodonia while receiving entecavir treatment.
Anahtar Kelimeler
Kaynakça
- 1. Karagoz E, Selek MB, Tanoglu A, Hatipoglu M, Ulçay A, Turhan V. Comparison of the elecsys HBsAg II assay and the architect assay for quantification of hepatitis B surface antigen in patients with chronic hepatitis B. Infez Med. 2016;24(4):287-292.
- 2. Karagöz E, Tanoğlu A. Importance of serum hepatitis B surface antigen and hepatitis e antigen quantification among patients with chronic hepatitis B. Turk J Gastroenterol. 2015;26:357.
- 3. Nikolopoulou GB, Tzoutzas I, Tsakris A, Maltezou HC. Hepatitis B in healthcare personnel: an update on the global landscape. Viruses. 2023;15(12):2454. doi: 10.3390/v15122454
- 4. Karagoz E, Ulcay A, Tanoglu A, et al. Clinical usefulness of mean platelet volume and red blood cell distribution width to platelet ratio for predicting the severity of hepatic fibrosis in chronic hepatitis B virus patients. Eur J Gastroenterol Hepatol. 2014;26(12):1320-1324.
- 5. Koklu S, Gulsen MT, Tuna Y, et al. Differences in nephrotoxicity risk and renal effects among anti-viral therapies against hepatitis B. Aliment Pharmacol Ther. 2015;41(3):310-319.
- 6. Deepinder F, Braunstein GD. Drug-induced gynecomastia: an evidence-based review. Expert Opin Drug Saf. 2012;11(5):779-795. doi: 10.1517/14740338.2012.712109
- 7. Berger O, Landau Z, Talisman R. Gynecomastia: a systematic review of pharmacological treatments. Front Pediatr. 2022;10:978311. doi: 10.3389/fped.2022.978311
- 8. Henriquez-Camacho C, Hijas-Gomez AI, Risco Risco C, Ruiz Lapuente MA, Escudero-Sanchez R, Cuerda VM. Lamivudine and entecavir for acute hepatitis B: a systematic review and meta-analysis. Viruses. 2023;15(11):2241. doi: 10.3390/v15112241
- 9. Bayramıçlı OU, Ahishali E, Dabak R, Ak Ö, Dolapçioğlu C. A case of gynecomastia due to entecavir. Turk J Gastroenterol. 2010;21(3):313-316. doi: 10.4318/tjg.2010.0108
Ayrıntılar
| Birincil Dil | İngilizce |
|---|---|
| Konular | Gastroenteroloji ve Hepatoloji |
| Bölüm | Letter to the Editor [en] Editöre Mektup [tr] |
| Yazarlar | |
| Yayımlanma Tarihi | 30 Nisan 2024 |
| Gönderilme Tarihi | 31 Mart 2024 |
| Kabul Tarihi | 25 Nisan 2024 |
| Yayımlandığı Sayı | Yıl 2024 Cilt: 5 Sayı: 2 |
|
|
|
|
|
|
|
|
Dergimiz; TR-Dizin ULAKBİM, ICI World of Journal's, Index Copernicus, Directory of Research Journals Indexing (DRJI), General Impact Factor, Google Scholar, Researchgate, WorldCat (OCLC), CrossRef (DOI), ROAD, ASOS İndeks, Türk Medline İndeks, Eurasian Scientific Journal Index (ESJI) ve Türkiye Atıf Dizini'nde indekslenmektedir.
EBSCO, DOAJ, OAJI, ProQuest dizinlerine müracaat yapılmış olup, değerlendirme aşamasındadır.
Makaleler "Çift-Kör Hakem Değerlendirmesi”nden geçmektedir.
Üniversitelerarası Kurul (ÜAK) Eşdeğerliği: Ulakbim TR Dizin'de olan dergilerde yayımlanan makale [10 PUAN] ve 1a, b, c hariç uluslararası indekslerde (1d) olan dergilerde yayımlanan makale [5 PUAN].
Note: Our journal is not WOS indexed and therefore is not classified as Q.
You can download Council of Higher Education (CoHG) [Yüksek Öğretim Kurumu (YÖK)] Criteria) decisions about predatory/questionable journals and the author's clarification text and journal charge policy from your browser. About predatory/questionable journals and journal charge policy
Not: Dergimiz WOS indeksli değildir ve bu nedenle Q sınıflamasına dahil değildir.
Yağmacı/şüpheli dergilerle ilgili Yüksek Öğretim Kurumu (YÖK) kararları ve yazar açıklama metni ile dergi ücret politikası: Yağmacı/Şaibeli Dergiler ve Dergi Ücret Politikası